DNA methylation at the mu-1 opioid receptor gene (OPRM1) promoter predicts preoperative, acute, and chronic postsurgical pain after spine fusion
Pharmacogenomics and Personalized Medicine Aug 16, 2017
Chidambaran V, et al. – The researchers evaluated deoxyribonucleic acid methylation at the mu-1 opioid receptor gene (OPRM1) promoter, as a predictor of preoperative, acute, and chronic postsurgical pain (CPSP) as DNA methylation was a potent repressor of gene expression. They identified novel CPSP biomarkers in an active regulatory region of the OPRM1 gene that binds multiple transcription factors. As per the outcomes, inhibition of binding by DNA methylation potentially decreased the OPRM1 gene expression, leading to a decreased response to endogenous and exogenous opioids, and an increased pain experience.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries